We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

They promised to relieve a painful arthritis in animals and become an important new franchise for maker Zoetis, the world’s ...

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic ...

In this article, we are going to take a look at where Zoetis Inc. (NYSE:ZTS) stands against Jim Cramer’s other stock picks. In a recent episode of Mad Money, Jim Cramer views the current market ...

Corcept Therapeutics (NASDAQ: CORT) shares soared 6.5% in the last trading session to close at $42.27. The move was backed by solid volume with far more shares changing hands than in a normal ...

Piper Sandler analyst David Westenberg maintained a Buy rating on Zoetis (ZTS – Research Report) today and set a price target of $210.00. The company’s shares closed yesterday at $188.38.

Stifel Nicolaus analyst Jonathan Block maintained a Buy rating on Zoetis (ZTS – Research Report) today and set a price target of $200.00. The company’s shares closed yesterday at $181.56.

Immune-complex vaccines will ensure long-term protection.

This Zoetis 2021 business report presents the course of business throughout the respective business year. The report complies with the disclosure requirement for corporate entities and generally ...

LOS ANGELES, CA / ACCESSWIRE / September 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ( ...

Elanco Animal Health Incorporated (NYSE: ELAN) today announced the U.S. Food and Drug Administration (FDA) has approved ...